Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

ss and comprehensive loss for the period 17,550,204 15,950,426 14,628,291 102,556,751 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Basic and diluted loss per share (0.42) (0.39) (0.40) ----------------------------------------------------------- ----------------------------------------------------------- Oncolytics Biotech Inc. CONSOLIDATED STATEMENTS OF CASH FLOWS For the periods ended December 31 Cumulative from inception on April 2, 1998 to December 31, 2008 2007 2006 2008 $ $ $ $ ------------------------------------------------------------------------- OPERATING ACTIVITIES Net loss and comprehensive loss for the period (17,550,204) (15,950,426) (14,628,291) (102,556,751) Add/(deduct) non-cash items Amortization - intellectual property 361,500 361,500 361,500 3,434,250 Amortization - property and equipment 48,754 40,714 52,638 497,151 Stock based compensation 64,039 539,156 403,550 4,768,844 Other non-cash items - - - 1,383,537 Net change in non-cash working capital 1,787,279 586,
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... July 26, 2014 Canada Endoscopy ... market data on the Canada Endoscopy Visualization Systems ... US dollars, volume (in units) and average prices ... Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization Systems and ... at http://www.marketresearchreports.biz/analysis/213254 . , The report also ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... 25, 2014 Amgen (NASDAQ: AMGN ... a $0.61 per share dividend for the third quarter ... 5, 2014, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
(Date:7/25/2014)... MA -- Trillions of bacteria live in each person,s ... help digest food and stave off harmful infections, but ... , To help shed light on the role of ... associate professor Eric Alm recently tracked fluctuations in the ... year. The findings, described in the July 25 issue ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... nanomaterial developed at Rensselaer Polytechnic Institute could enable the ... electric automobiles, as well as batteries for laptop computers, ... material, dubbed a "nanoscoop" because its shape resembles a ... can withstand extremely high rates of charge and discharge ...
... Corporation (Nasdaq: SIAL ) will be presenting at ... 10th at 10:00 AM PT in San Francisco, CA. Interested ... available at http://investor.sigmaaldrich.com/ .  Users can click the ... About Sigma-Aldrich: Sigma-Aldrich is a leading Life ...
... Rx Communications Group, LLC will host a panel discussion ... with financial as well as trade journalists. The event ... in San Francisco on Tuesday, January 11, 2011 from ... focus on media interview preparation and understanding the differing ...
Cached Biology Technology:'Nanoscoops' could spark new generation of electric automobile batteries 2'Nanoscoops' could spark new generation of electric automobile batteries 3Rx Communications Group to Host Panel Discussion for Biotechnology Executives on Communicating with the Media 2Rx Communications Group to Host Panel Discussion for Biotechnology Executives on Communicating with the Media 3
(Date:7/27/2014)... that nicotine and cotinine, a metabolite of nicotine, can ... in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is ... ends up in the tobacco smoke. Once inhaled, it ... is activated by a variety of enzymes called Cytochrome ... nicotine can partially interfere with the activation of NNK, ...
(Date:7/27/2014)... might have survived the asteroid strike that wiped them ... later in history, scientists say. , A fresh study ... helped palaeontologists to build a new narrative of the ... They found that in the few million years before ... was experiencing environmental upheaval. This included extensive volcanic activity, ...
(Date:7/27/2014)... to date, researchers from the U.K. provide national, regional, ... virus (HCV). Findings published in Hepatology, a journal of ... indicate that genotype 1 is the most prevalent worldwide, ... reside in East Asia. Genotype 3, at just over ... by genotypes 2, 4, 6, and 5. , ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2Hepatitis C virus genotype 1 is most prevalent worldwide 2
... July 11, 2013 /PRNewswire-iReach/ -- Chris Christie , Governor ... lost a significant amount of weight after undergoing lap band ... in USA Today, Governor Christie was inspired to have the ... clothes no longer fit. (Photo: http://photos.prnewswire.com/prnh/20130711/CG45941 ) ...
... are obese and hope to be a father, here,s ... may inherit your waistline or metabolic disorders. That,s because ... those who did not show any signs of diabetes, ... daughters. Sons don,t entirely dodge this genetic bullet ...
... experimental study in rats has shown that consuming choline, ... eggs and chicken or beef liver, soy and wheat ... study, conducted by scientists at the University of Granada ... York (United Kingdom), has revealed that choline is directly ...
Cached Biology News:Chris Christie, Governor of New Jersey, Slims Down after Having Lap Band Surgery 2Obese dads pass on predisposition to obesity and metabolic disorders to their kids 2Choline intake improves memory and attention-holding capacity 2
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
... Cosmid Cloning Kit enables you to prepare, ... unbiased primary cosmid library of genomic DNA ... sublibraries. High efficiency cosmid library construction is ... protocols. First, genomic DNA is randomly sheared ...
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
... VersaDoc MP 4000 System is a ... system capable of supporting a wide ... chemiluminescence, densitometry, and chemiflourescence. Red, ... imaging of multiplexed fluorescent samples, reducing ...
Biology Products: